Emergent BioSolutions | EBS - Ebitda

Stock Price
10.93
Daily Change
-0.06 -0.55%
Monthly
-4.96%
Yearly
41.76%
Q1 Forecast
10.65

Emergent BioSolutions reported $-113.5M in EBITDA for its fiscal quarter ending in March of 2023.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
ANI Pharmaceuticals USD 59.6M 5.52M Sep/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Coherus Biosciences USD -44.34M 9.82M Mar/2025
Exact Sciences USD 135.42M 2.8M Sep/2025
Exelixis USD 248.93M 28.02M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Lonza CHF 1.01B 54M Dec/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Myriad Genetics USD 10.3M 4.2M Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Pacira USD 49.36M 4.96M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Xoma USD 2.52M 7.98M Jun/2024